Literature DB >> 26021196

Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.

Matthew J Whitson1, Gary W Falk2.   

Abstract

The prevalence of esophageal adenocarcinoma is increasing dramatically. Barrett's esophagus remains the most well-established risk factor for the development of esophageal adenocarcinoma. There are multiple clinical, endoscopic, and pathologic factors that increase the risk of neoplastic progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett's esophagus. This article reviews both risk and protective factors for neoplastic progression in patients with Barrett's esophagus.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barrett’s esophagus; Dysplasia; Esophageal adenocarcinoma; Neoplastic progression; Risk factors

Mesh：

Substances：

Year:  2015        PMID： 26021196      PMCID： PMC4449455          DOI： 10.1016/j.gtc.2015.02.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  104 in total

1.  Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Authors:  M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

2.  Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.

Authors:  F Hvid-Jensen; L Pedersen; P Funch-Jensen; A M Drewes
Journal:  Aliment Pharmacol Ther       Date:  2014-03-11       Impact factor: 8.171

3.  A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma.

Authors:  F Turati; I Tramacere; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

Review 4.  Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis.

Authors:  Irene Tramacere; Carlo La Vecchia; Eva Negri
Journal:  Epidemiology       Date:  2011-05       Impact factor: 4.822

5.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

6.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

Review 7.  Epidemiology and risk factors for oesophageal adenocarcinoma.

Authors:  Côme Lepage; Antoine Drouillard; Jean-Louis Jouve; Jean Faivre
Journal:  Dig Liver Dis       Date:  2013-02-28       Impact factor: 4.088

8.  Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.

Authors:  P C Konturek; G Burnat; E G Hahn
Journal:  J Physiol Pharmacol       Date:  2007-08       Impact factor: 3.011

9.  Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.

Authors:  Ian L P Beales; Inna Vardi; Leanne Dearman
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 2.566

10.  Intakes of folate, methionine, vitamin B6, and vitamin B12 with risk of esophageal and gastric cancer in a large cohort study.

Authors:  Q Xiao; N D Freedman; J Ren; A R Hollenbeck; C C Abnet; Y Park
Journal:  Br J Cancer       Date:  2014-01-30       Impact factor: 7.640
View more
  1 in total

1.  The evolutionary history of 2,658 cancers.

Authors:  Moritz Gerstung; Clemency Jolly; Ignaty Leshchiner; Stefan C Dentro; Santiago Gonzalez; Daniel Rosebrock; Thomas J Mitchell; Yulia Rubanova; Pavana Anur; Kaixian Yu; Maxime Tarabichi; Amit Deshwar; Jeff Wintersinger; Kortine Kleinheinz; Ignacio Vázquez-García; Kerstin Haase; Lara Jerman; Subhajit Sengupta; Geoff Macintyre; Salem Malikic; Nilgun Donmez; Dimitri G Livitz; Marek Cmero; Jonas Demeulemeester; Steven Schumacher; Yu Fan; Xiaotong Yao; Juhee Lee; Matthias Schlesner; Paul C Boutros; David D Bowtell; Hongtu Zhu; Gad Getz; Marcin Imielinski; Rameen Beroukhim; S Cenk Sahinalp; Yuan Ji; Martin Peifer; Florian Markowetz; Ville Mustonen; Ke Yuan; Wenyi Wang; Quaid D Morris; Paul T Spellman; David C Wedge; Peter Van Loo
Journal:  Nature       Date:  2020-02-06       Impact factor: 49.962
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.